BACKGROUND AND OBJECTIVES: The study aim was to establish the incidence and characterize all encapsulating peritoneal sclerosis (EPS) cases in patients treated by peritoneal dialysis (PD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The patient cohort, which started PD from January 1, 2000, to December 31, 2007, was identified from the Scottish Renal Registry (n = 1238). Possible EPS cases were identified by the ten adult Scottish renal units. Patient records were examined to ensure cases met diagnostic criteria. RESULTS: Forty-six cases were identified; 19 had their first PD exposure after January 1, 2000. The rate was 1.5%, an incidence of 4.9 per 1000 person-years. The incidence increased with PD duration, with rates of 0, 0.6, 2.0, 3.5, 8.1, 8.8 and 5% at <1, 1 to 2, >2 to 3, >3 to 4, >4 to 5, >5 to 6 and >6 yr PD exposure, respectively. The median PD duration of EPS cases was 5.1 yr (interquartile range [IQR] 3.4 to 6.1 yr). At diagnosis, 12 (26%) were on PD and 33 (72%) were diagnosed <2 yr after PD stopped. The cases had a median of 3.3 episodes of peritonitis (range 0 to 20, IQR 1 to 4.5). Thirty (65%) had used 3.86% dextrose dialysate and 45 (98%) had used Extraneal. The mortality was 42% at 1 yr postdiagnosis with a median survival of 149 d (IQR 61 to 408 d). CONCLUSIONS: The incidence reported in this study may be used to inform patients of the minimum risk of developing EPS on PD.
BACKGROUND AND OBJECTIVES: The study aim was to establish the incidence and characterize all encapsulating peritoneal sclerosis (EPS) cases in patients treated by peritoneal dialysis (PD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The patient cohort, which started PD from January 1, 2000, to December 31, 2007, was identified from the Scottish Renal Registry (n = 1238). Possible EPS cases were identified by the ten adult Scottish renal units. Patient records were examined to ensure cases met diagnostic criteria. RESULTS: Forty-six cases were identified; 19 had their first PD exposure after January 1, 2000. The rate was 1.5%, an incidence of 4.9 per 1000 person-years. The incidence increased with PD duration, with rates of 0, 0.6, 2.0, 3.5, 8.1, 8.8 and 5% at <1, 1 to 2, >2 to 3, >3 to 4, >4 to 5, >5 to 6 and >6 yr PD exposure, respectively. The median PD duration of EPS cases was 5.1 yr (interquartile range [IQR] 3.4 to 6.1 yr). At diagnosis, 12 (26%) were on PD and 33 (72%) were diagnosed <2 yr after PD stopped. The cases had a median of 3.3 episodes of peritonitis (range 0 to 20, IQR 1 to 4.5). Thirty (65%) had used 3.86% dextrose dialysate and 45 (98%) had used Extraneal. The mortality was 42% at 1 yr postdiagnosis with a median survival of 149 d (IQR 61 to 408 d). CONCLUSIONS: The incidence reported in this study may be used to inform patients of the minimum risk of developing EPS on PD.
Authors: K Yokoyama; H Yoshida; N Matsuo; Y Maruyama; Y Kawamura; R Yamamoto; K Hanaoka; M Ikeda; H Yamamoto; M Nakayama; Y Kawaguchi; T Hosoya Journal: Clin Nephrol Date: 2008-02 Impact factor: 0.975
Authors: Gloria del Peso; M Auxiliadora Bajo; Fernando Gil; Abelardo Aguilera; Silvia Ros; Olga Costero; M Jose Castro; Rafael Selgas Journal: Adv Perit Dial Date: 2003
Authors: Imad Siddique; K Scott Brimble; Louise Walkin; Angela Summers; Paul Brenchley; Sarah Herrick; Peter J Margetts Journal: Perit Dial Int Date: 2014-11-13 Impact factor: 1.756
Authors: Erika De Sousa-Amorim; Gloria Del Peso; M Auxiliadora Bajo; Laura Alvarez; Marta Ossorio; Fernando Gil; Teresa Bellon; Rafael Selgas Journal: Perit Dial Int Date: 2014-03-01 Impact factor: 1.756
Authors: Catriona Goodlad; Frederick W K Tam; Sohail Ahmad; Gurjeet Bhangal; Bernard V North; Edwina A Brown Journal: Perit Dial Int Date: 2014-03-01 Impact factor: 1.756